Diabetes
Conference Coverage
Could a type 2 diabetes drug tackle kidney stones?
“If this association is proven, empagliflozin may be used to decrease the risk of kidney stones at least in those with type 2 diabetes, but maybe...
News
What’s the best time of day to exercise? It depends on your goals
When you exercise can ultimately have a big effect in terms of strength, fat loss, heart health, mood, and quality of sleep.
Conference Coverage
Experts elevate new drugs for diabetic kidney disease
A consensus statement from the ADA and KDIGO recommends more aggressive combined use of several newer, and costly, drug classes to slow...
Conference Coverage
Diabetes tied to risk of long COVID, too
Roughly 43% of studies in a literature review identified diabetes as a risk factor for postacute sequelae of COVID-19.
Conference Coverage
Prediabetes is linked independently to myocardial infarction
A history of prediabetes is predictor of MI independent of any other risk factor, suggesting that screening efforts should increase.
Conference Coverage
SGLT2 inhibitors cut AFib risk in real-word analysis
Observational data add to a growing link between SGLT2 inhibitor treatment and atrial fibrillation prevention in people with type 2 diabetes.
News
New guideline for in-hospital care of diabetes says use CGMs
Patients with diabetes or newly recognized hyperglycemia get admitted to every patient service in the hospital, and their glycemic management can...
News
ADA updates on finerenone, SGLT2 inhibitors, and race-based eGFR
ADA has made an interim change to its latest Standards of Medical Care, an update based on trial evidence and consensus about finerenone, SGLT2...
Conference Coverage
‘Remission is possible’ for patients with type 2 diabetes
In a small study conducted in India, most patients had remission type 2 diabetes at 6 months with an intervention that included a smart app that...
Conference Coverage
Antidiabetes drug costs keep patients away
Patients with diabetes and high med co-pays had worse fill rates, but even with low copays uptake of effective but expensive antidiabetes drugs...